Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time
Smith, Peter K × Carrier, Michel Chen, John C Haverich, Axel Levy, Jerrold H Menasche, Philippe Shernan, Stanton K Van de Werf, Frans Adams, Peter X Todaro, Thomas G Verrier, Edward #
Annals of Thoracic Surgery vol:82 issue:3 pages:781-789
52nd Annual Meeting of the Southern-Thoracic-Surgical-Association location:Orlando date:10 - 12 Nov 2005
Background. Prolonged cross-clamp time during cardiac surgery increases the risk of postoperative mortality and myocardial injury. This subanalysis from the pexelizumab for reduction of infarction and mortality in coronary artery bypass grafting surgery ( PRIMO-CABG) trial, a phase III double-blind, placebo-controlled study of 3,099 patients undergoing on-pump coronary artery bypass graft surgery with or without valve surgery, assessed the impact of pexelizumab, an investigational C5 complement inhibitor, on postoperative outcomes after prolonged aortic cross-clamp time.